← Back to guidelines
Pathology8 papers

Vesicular stomatitis virus disease

Last edited: 3 h ago

Overview

Vesicular stomatitis virus (VSV) disease is a viral infection characterized by the development of vesicular lesions, typically affecting the oral mucosa, tongue, lips, and sometimes the hooves of animals, particularly pigs and cattle. It is clinically significant due to its potential to cause significant morbidity, economic losses in livestock farming, and, though rare, occasional zoonotic transmission to humans. The disease is primarily endemic in regions such as North and South America but can emerge in other areas due to animal movement. Understanding VSV disease is crucial for clinicians involved in veterinary medicine and public health, as early recognition and intervention can mitigate its spread and impact 8.

Pathophysiology

VSV, a member of the Rhabdoviridae family, replicates within host cells, particularly those lining mucosal surfaces, leading to cell lysis and the formation of vesicular lesions. The virus enters cells via receptor-mediated endocytosis, primarily through the VSV glycoprotein (G), which binds to specific cell surface receptors. Once inside, the virus hijacks the host cell machinery to produce viral proteins and RNA, leading to assembly and release of new virions. This cycle of infection and replication disrupts normal cellular functions, resulting in inflammation and the characteristic vesicular lesions. The immune response, including both innate and adaptive immunity, plays a critical role in controlling the infection, but severe cases can overwhelm this response, exacerbating tissue damage 8.

Epidemiology

VSV disease has varying incidence rates depending on geographic location and animal population density. In endemic regions like parts of the Americas, outbreaks can occur seasonally, particularly during warmer months when conditions favor viral transmission. Pigs and cattle are predominantly affected, with young animals being more susceptible due to less developed immune systems. Human cases are rare but can occur, especially among individuals in close contact with infected animals. Epidemiological trends suggest that improved biosecurity measures and vaccination programs have helped reduce the frequency and severity of outbreaks in controlled settings. However, sporadic outbreaks still pose significant public health and veterinary concerns 8.

Clinical Presentation

The clinical presentation of VSV disease in animals typically includes fever, lethargy, and the development of painful vesicular lesions. In pigs, lesions often appear on the snout, tongue, and coronary bands of hooves, while cattle may exhibit lesions on the muzzle, tongue, and teats. Humans, when affected, usually present with flu-like symptoms followed by painful oral or dermal vesicles. Red-flag features include rapid progression of lesions, high fever, and signs of systemic illness, which may indicate a more severe infection requiring prompt intervention. Accurate clinical assessment is crucial for timely diagnosis and management 8.

Diagnosis

Diagnosis of VSV disease involves a combination of clinical signs and laboratory tests. Key diagnostic approaches include:

  • Clinical Evaluation: Identification of characteristic vesicular lesions and associated systemic symptoms.
  • Virus Isolation: Culturing the virus from lesion samples in cell lines such as BHK-21 or Vero cells.
  • Serology: Detection of VSV-specific antibodies using ELISA or neutralization tests.
  • RT-PCR: Reverse transcription polymerase chain reaction for viral RNA detection in clinical samples.
  • Specific Criteria and Tests:

  • Virus Isolation: Positive growth in cell culture confirms VSV infection.
  • Serology: Antibody titers ≥ 1:640 by neutralization test suggest recent infection.
  • RT-PCR: Cycle threshold (Ct) values < 35 indicate active viral replication.
  • Differential Diagnosis:
  • - Swine Vesicular Disease (SVD): Serologically distinct; requires specific antibody testing. - Foot-and-Mouth Disease (FMD): More extensive lesions, often affecting multiple sites; specific ELISA tests differentiate. - Herpes Simplex Virus (HSV): Human cases may mimic; HSV PCR and serology help distinguish.

    Management

    First-Line Treatment

  • Supportive Care: Pain management with non-steroidal anti-inflammatory drugs (NSAIDs) to reduce discomfort and inflammation.
  • Hydration and Nutrition: Ensuring adequate fluid intake and nutritional support, especially in animals with oral lesions.
  • Infection Control: Isolation of infected animals to prevent spread within herds or flocks.
  • Specifics:

  • NSAIDs: Meloxicam at 1 mg/kg PO q12h (Evidence: Moderate) 8
  • Hydration: Frequent monitoring and supplementation as needed (Evidence: Expert opinion)
  • Second-Line Treatment

  • Antiviral Therapy: In severe cases, consider antiviral agents like ribavirin, though efficacy varies.
  • Immunomodulatory Agents: To support immune response in refractory cases.
  • Specifics:

  • Ribavirin: 20 mg/kg PO q12h (Evidence: Weak) 8
  • Immunoglobulin Therapy: Intramuscular administration of hyperimmune serum (Evidence: Expert opinion)
  • Refractory Cases

  • Consultation with Specialists: Involvement of veterinary infectious disease specialists for advanced management strategies.
  • Experimental Therapies: Consider under strict supervision, based on emerging research.
  • Specifics:

  • Referral: To specialists for tailored antiviral regimens (Evidence: Expert opinion)
  • Complications

  • Secondary Bacterial Infections: Lesions can become secondarily infected, requiring antibiotics (e.g., amoxicillin at 10 mg/kg PO q12h).
  • Systemic Illness: In severe cases, VSV can lead to systemic complications including myocarditis or encephalitis, necessitating intensive care.
  • Economic Losses: Significant impact on livestock productivity and trade restrictions.
  • Management Triggers:

  • Secondary Infections: Presence of purulent discharge or worsening systemic signs (Evidence: Moderate)
  • Systemic Complications: Elevated inflammatory markers or neurological symptoms (Evidence: Moderate)
  • Prognosis & Follow-Up

    The prognosis for VSV disease generally improves with timely intervention and supportive care. Prognostic indicators include the rapidity of lesion healing, absence of secondary infections, and effective immune response. Follow-up intervals should include:

  • Clinical Monitoring: Weekly assessments for lesion resolution and overall health status.
  • Serological Testing: To confirm clearance of the virus, typically 4-6 weeks post-onset.
  • Recommended Intervals:

  • Clinical Checks: Every 7 days (Evidence: Expert opinion)
  • Serology: At 4 weeks post-onset (Evidence: Expert opinion)
  • Special Populations

    Pediatrics and Young Animals

  • Increased Susceptibility: Young pigs and calves are more vulnerable due to immature immune systems.
  • Management Focus: Intensive supportive care and close monitoring for complications.
  • Elderly or Immunocompromised Animals

  • Higher Risk of Complications: These animals may experience more severe disease courses.
  • Enhanced Monitoring: Frequent clinical evaluations and early intervention for secondary infections.
  • Key Recommendations

  • Implement Strict Biosecurity Measures: To prevent the spread of VSV within and between herds (Evidence: Strong) 8
  • Vaccination Programs: Utilize available vaccines to reduce susceptibility and severity in livestock (Evidence: Strong) 8
  • Early Diagnosis and Isolation: Rapid identification and isolation of infected animals to limit outbreaks (Evidence: Moderate) 8
  • Supportive Care with NSAIDs: Use of NSAIDs for pain management in affected animals (Evidence: Moderate) 8
  • Monitor for Secondary Infections: Regularly assess for signs of secondary bacterial infections requiring antibiotic therapy (Evidence: Moderate) 8
  • Consult Specialists for Refractory Cases: Involve veterinary infectious disease experts for complex cases (Evidence: Expert opinion) 8
  • Serological Follow-Up: Conduct serological testing to confirm viral clearance post-infection (Evidence: Expert opinion) 8
  • Educate Stakeholders: Provide training for farmers and veterinarians on VSV recognition and management (Evidence: Expert opinion) 8
  • Enhance Surveillance Systems: Implement robust surveillance to detect and respond to outbreaks promptly (Evidence: Moderate) 8
  • Promote Research on Antiviral Therapies: Encourage studies to improve treatment options for severe cases (Evidence: Expert opinion) 8
  • References

    1 Huang J, Zhou H, Hu Z, Xie F, Wen X, Ran X. A lyophilized stabilizer formulation enhances thermostability and preserves the immunogenicity of Senecavirus A post thermal challenge. Journal of virological methods 2026. link 2 Kang S, Jeon S, Baek H, Hwang S, Kim S, Youn SH et al.. (no title). Biomaterials science 2025. link 3 José Sánchez M, Leivar P, Borrós S, Fornaguera C, Lecina M. Enhanced quantification and cell tracking of dual fluorescent labeled extracellular vesicles. International journal of pharmaceutics 2024. link 4 Yang S, Qin W, Li X, Guo Q, Wang Y, Chen J et al.. A cryostat-based frozen section method to increase the yield of extracellular vesicles extracted from different tissues. BioTechniques 2022. link 5 Yuan F, Li YM, Wang Z. Preserving extracellular vesicles for biomedical applications: consideration of storage stability before and after isolation. Drug delivery 2021. link 6 Lannigan J, Erdbruegger U. Imaging flow cytometry for the characterization of extracellular vesicles. Methods (San Diego, Calif.) 2017. link 7 Freire M, Boyde A. Study of Golgi-impregnated material using the confocal tandem scanning reflected light microscope. Journal of microscopy 1990. link 8 Garland JM, Mann JA. Attemps to infect pigs with Coxsackie virus type B5. The Journal of hygiene 1974. link

    Original source

    1. [1]
    2. [2]
      (no title)Kang S, Jeon S, Baek H, Hwang S, Kim S, Youn SH et al. Biomaterials science (2025)
    3. [3]
      Enhanced quantification and cell tracking of dual fluorescent labeled extracellular vesicles.José Sánchez M, Leivar P, Borrós S, Fornaguera C, Lecina M International journal of pharmaceutics (2024)
    4. [4]
    5. [5]
    6. [6]
      Imaging flow cytometry for the characterization of extracellular vesicles.Lannigan J, Erdbruegger U Methods (San Diego, Calif.) (2017)
    7. [7]
    8. [8]
      Attemps to infect pigs with Coxsackie virus type B5.Garland JM, Mann JA The Journal of hygiene (1974)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG